Copeptin as a novel biomarker of cardiometabolic syndrome

Szmygin, Hanna; Szydełko, Joanna; Matyjaszek‐Matuszek, Beata

doi:10.5603/ep.a2021.0072

Cited by 9 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies indicated that AVP contributes to the development and progression of diabetic microangiopathy and serum copeptin may serve as an independent marker of renal, heart or retinal microcirculation involvement in type 2 diabetes patients. 38 In our SSc group, higher concentrations of serum copeptin were observed in patients presenting "late" NVC pattern, which is characterized by irregular enlargement of the capillaries, few or absent giant capillaries and haemorrhages, ramified and bushy capillaries and progressive capillary loss (50-70%) with formation of extensive avascular areas (vascular desertification). These alterations, namely abnormal vessel morphology, changes in capillary number and disorganization of microcirculation architecture observed in the "late" NVC pattern stem from insufficient angio-and vasculogenesis.…”

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

“…While copeptin has not been studied in SSc so far, its properties as a biomarker of microcirculation abnormalities were studied in diabetic angiopathy. 38 Baseline serum copeptin is associated with cumulative incidence of lower-extremity amputations in cohorts of patients with type 1 and type 2 diabetes and may help to identify high-risk individuals. 45 Further studies are needed to confirm prospectively that copeptin may serve as a diagnostic tool for discriminating increased risk of DUs development.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis

Maciejewska¹,

Stec²,

Zaremba³

et al. 2023

CCID

View full text Add to dashboard Cite

Background Systemic sclerosis is a connective tissue disease characterized by vasculopathy and progressive fibrosis, leading to multiorgan dysfunction. Given the complex and not fully elucidated pathogenesis, biomarkers of rapid disease progression and therapeutic response are lacking. Copeptin, which reflects vasopressin activity in serum, is used in diagnosing or prognosing different cardiometabolic conditions. Objective The aim of study was to investigate the concentration of copeptin in patients with systemic sclerosis and correlate it with specific clinical symptoms. Patients and Methods Serum copeptin was measured in patients with systemic sclerosis (34 women and 3 men; mean age 57.6 years) and in healthy individuals (n=30) using commercially available ELISA kits. According to the criteria of LeRoy our systemic sclerosis cohort consisted of 17 patients with limited cutaneous systemic sclerosis (45.9%) and 20 diffuse cutaneous systemic sclerosis patients (54.1%). According to the criteria of LeRoy our systemic sclerosis cohort consisted of 17 patients with limited cutaneous systemic sclerosis (45.9%) and 20 diffuse cutaneous systemic sclerosis patients (54.1%). The median duration of the disease was 10 [4–14] years. Results We found significantly higher copeptin concentration in patients with systemic sclerosis (4.21 pmol/L [3.04–5.42]) in comparison to control group (3.40 pmol/L [2.38–3.76], p<0.01). Copeptin significantly correlated with Raynaud’s condition score (r=0.801, p<0.05). Patients with “late” capillaroscopic patterns had higher copeptin concentrations (5.37 pmol/L [4.29–8.06]) than patients with “early” (2.43 pmol/L [2.25–3.20], p<0.05) and “active” patterns (3.93 pmol/L [2.92–5.16], p<0.05]). Copeptin was found to be significantly higher in SSc patients with DUs (5.71 pmol/L [IQR 4.85–8.06]) when compared to SSc patients without DUs (3.31 pmol/L, [2.28–4.30], p<0.05). Additionally, copeptin concentration had good diagnostic accuracy in discriminating between patients with and without digital ulcers (AUC=0.863). Alprostadil decreased copeptin concentration from 4.96 [4.02–6.01] to 3.86 pmol/L [3.17–4.63] (p<0.01) after 4–6 cycles of administration. Conclusion Our findings suggest that copeptin may be a promising biomarker of microcirculation alterations in systemic sclerosis.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis

Maciejewska¹,

Stec²,

Zaremba³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…ADH has a very short half-life and is difficult to measure. Copeptin, which is found at the C-terminus of anti-diuretic hormone prodrugs, is the most commonly used marker for detecting plasma ADH ( Christ-Crain, 2019 ; Kim et al, 2021 ; Szmygin et al, 2021 ). The results of this study revealed that the morphological changes of the hypothalamic were obvious, and the expression of copeptin, ADH mRNA, and AQP 2 was increased in the model group rats, indicating that oliguria in acute alcoholism was caused by excessive secretion of ADH from hypothalamic tissues to promote water reabsorption by the kidney.…”

Section: Discussionmentioning

confidence: 99%

Integrating network pharmacology and experimental verification to explore the mechanism of puerarin against oliguria in acute alcoholism

Wan

Huang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Purpose: This study was designed to evaluate the pharmacological mechanisms of puerarin against oliguria in acute alcoholism via network pharmacology analysis combined with experimental verification.Methods: First, this study established an acute alcoholism rat model, compared the changes in urine volume in each group, and observed the therapeutic effect of puerarin by H&E staining, biochemical, RT-qPCR, and immunohistochemical analyses. Second, puerarin-related targets were searched in TCMS, PubChem, CNKI, Wanfang, PubMed, and GeenMedical Academic databases. Also, potential disease targets were obtained from the GeneCards, MalaCards, and NCBI-gene databases and genes with puerarin target gene intersections were screened out. The interaction network for co-predicted targets was obtained using the STRING database, and the core targets were imported into Cytoscape for visualization using DAVID Bioinformatics Resources 6.8. The essential genes were subjected to the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathway enrichment analyses to predict related biological processes and significant signaling pathways. Finally, molecular docking was used to examine the interaction of puerarin with key targets, and the core targets were validated further by RT-qPCR and Western blotting.Results: Compared to the model group, the urine volume of the rats was significantly increased after puerarin treatment, and the levels of anti-diuretic hormone (ADH) and aquaporin 2 (AQP2) expression were decreased. Searching the intersection of puerarin and acute alcoholism targets yielded 214 potential targets, 837 biological processes, and 185 signaling pathways involved. The molecular docking results indicated a good affinity between puerarin and key targets (cyclic adenosine monophosphate (cAMP), protein kinase A (PKA), cAMP-response element-binding protein (CREB), and c-Fos). RT-qPCR and Western blotting further verified that puerarin could down-regulate the expression of cAMP/PKA/CREB/c-Fos.Conclusion: This study identified the potential targets of puerarin against oliguria in rats with acute alcoholism using network pharmacology and animal experiments. The mechanism may be closely related to the cAMP signaling pathway.

show abstract

“…However, as a small peptide of nine amino acids, the blood level of AVP is difficult to quantitatively analyze due to its short half-life[ 10 ]. Copeptin is a 39-amino-acid glycopeptide which contains the C-terminus of AVP precursor, making it an effective surrogate marker for AVP release[ 11 , 12 ]. As a result of osmotic stress and osmotic stimulation, a high level of copeptin has been demonstrated in patients with ACLD[ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Circulating copeptin level and the clinical prognosis of patients with chronic liver disease

Tan,

Zhao,

Huang

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignancy with a high incidence and fatality rate worldwide. Hepatitis B virus (HBV) infection is one of the most important risk factors for its occurrence and development. Early detection of HBV-associated HCC (HBV-HCC) can improve clinical decision-making and patient outcomes. Biomarkers are extremely helpful, not only for early diagnosis, but also for the development of therapeutics. MicroRNAs (miRNAs), a subset of non-coding RNAs approximately 22 nucleotides in length, have increasingly attracted scientists’ attention due to their potential utility as biomarkers for cancer detection and therapy. HBV profoundly impacts the expression of miRNAs potentially involved in the development of hepatocarcinogenesis. In this review, we summarize the current progress on the role of miRNAs in the diagnosis and treatment of HBV-HCC. From a molecular standpoint, we discuss the mechanism by which HBV regulates miRNAs and investigate the exact effect of miRNAs on the promotion of HCC. In the near future, miRNA-based diagnostic, prognostic, and therapeutic applications will make their way into the clinical routine.

show abstract

Copeptin as a novel biomarker of cardiometabolic syndrome

Cited by 9 publications

References 42 publications

Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis

Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis

Integrating network pharmacology and experimental verification to explore the mechanism of puerarin against oliguria in acute alcoholism

Circulating copeptin level and the clinical prognosis of patients with chronic liver disease

Contact Info

Product

Resources

About